Enlivex Therapeutics is trading 7.7% up today at $2.10 as investors partially reverse a sharp selloff triggered by a recent dilutive financing deal.
- The move follows a series of steep declines after a highly dilutive, crypto-linked $400 million private placement.
- Shares are currently stabilizing as the market reassesses the long-term impact of the deal amid broader weakness in the biotechnology sector.